[1] Data and Trends . http://www. cdc. gov/diabetes/surveillance/index. htm[2] IDF Diabetes Atlas update 2012. http://www. idf. org/diabetesatlas/5e/Update2012[3] MOHAMMED K A, CH B, KAI M B, et al. Achievement of goals in US diabetes care, 1999-2010. N Engl J Med, 2013,368(17):1613-1624. [4] UKPDS GROUP. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 1998,352(9131):854-865. [5] UKPDS GROUP. U K prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease. UK Prospective Diabetes Study Group. Diabetes, 1995, 44(11): 1249-1258. [6] DEACON C F, NAUCK M A, TOFT-NIELSEN M,et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH₂-terminus in type II diabetic patients and in healthy subjects. Diabetes, 1995,44(9):1126-1131. [7] BRUBAKER P L. Incretin-based therapies: Mimetics versus protease inhibitors. Trends Endocrinol Metab, 2007,18(6):240-245. [8] INZUCCHI S E, BERGENSTAL R M, BUSE J B, et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) . Diabetes Care, 2012,35(6):1364-1379. [9] GARBER A J, ABRAHAMSON M J, BARZILAY J I, et al. AACE Comprehensive diabetes management algorithm 2013. Endocr Pract, 2013,19(2):327-336. [10] 2011 IDF Treatment Algorithm for People with Type 2 Diabetes. http://www. idf. org/treatment-algorithm-people-type-2-diabetes[11] Chinese Medical Association Diabetes Society. The guideline of treatment and prevention for Chinese type 2 diabetes 2010. http://www. diab. net. cn/uploadfile/T2dmguideline 2010. pdf. [12] ASCHNER P, KATZEFF H L, GUO H, et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab, 2010,12(3):252-261. [13] BARZILAI N, GUO H, MAHONEY E M, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Curr Med Res Opin, 2011,27(5):1049-1058. [14] MOHAN V, YANG W, SON H Y, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract, 2009,83(1):106-116. [15] NAUCK M A, MEININGER G, SHENG D, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: A 2-year study. Diabetes Obes Metab, 2007,9(2):194-205. [16] SECK T, NAUCK M, SHENG D, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: A 2-year study. Int J Clin Pract, 2010,64(5):562-576. [17] RAZ I, CHEN Y, WU M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes . Curr Med Res Opin, 2008,24(2):537-550. [18] REASNER C, OLANSKY L, SECK T L, et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab, 2011,13(7):644-652. [19] HONG E S, KHANG A R, YOON J W, et al. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. Diabetes Obes Metab, 2012,14(9):795-802. [20] SCHEEN A J, CHARPENTIER G, OSTGREN C J, et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev, 2010,26(7):540-549. [21] RIZZO M R, BARBIERI M, MARFELLA R, et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: Role of dipeptidyl peptidase-IV inhibition. Diabetes Care, 2012,35(10):2076-2082. [22] GUERCI B, MONNIER L, SERUSCLAT P, et al. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: Results from the randomized optima study. Diabetes Metab, 2012,38(4):359-366. [23] PHUNG O J, SCHOLLE J M, TALWAR M, et al. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA, 2010,303(14):1410-1418.[24] KIM Y G, HAHN S, OH T J, et al. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: A systematic review and meta-analysis. Diabetologia,2013,56(4):696-708.[25] WILLIAMS-HERMAN D, ENGEL S S, ROUND E, et al. Safety and tolerability of sitagliptin in clinical studies: A pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord, 2010,10:7.[26] WHITE W B, BAKRIS G L, BERGENSTAL R M, et al. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): A cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J, 2011,162(4):620-626.[27] SCIRICA B M, BHATT D L, BRAUNWALD E, et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am Heart J,2011,162(5):818-825.